Investor Presentaiton
13
Focused Execution into 2018
UP
Expanding into formulation business by synergizing with our APIs
- Complete the production of 4 registration batch drug products
- Establish partnership for self-developed drug products
Strengthening Manufacturing and Quality
- Create leaner and flexible cost structures by improving operating efficiency, RD
productivity and portfolio optimization
- Comply with the modern strict environmental laws in China
Near term CRO projects pose to propel the company to next level
- Focus on targeted therapies and orphan drugs /first in class or best in class
- Provide integrated service from API to formulation for niche injectable
Continuous process optimization on our existing APIs
Maintain market share and profits of our major products
ScinoPharmView entire presentation